One blood draw. Four simple steps. Multiple liver insights. LIVERFASt™ was designed to support liver health assessment through a simple and scalable workflow that integrates into real-world clinical practice. Using 10 common biomarkers from just 1 blood sample, LIVERFASt™ generates three key scores providing insights across: • Fibrosis • Steatosis • Activity Ordering LIVERFASt™ is designed to be straightforward: 01 - Physician prescribes LIVERFASt™ 02 - Lab analyzes 10 biomarkers from 1 blood sample 03 - Biomarker values entered into the platform 04 - LIVERFASt™ results available immediately Simple workflows help support broader accessibility to liver disease assessment while enabling earlier identification, clearer stratification, and more informed clinical decisions in MASLD/MASH care. Because meaningful liver insights should be both actionable and accessible. #LIVERFASt #MASLD #NonInvasiveDiagnostics #LiverHealth #Screening #Monitoring #ClinicalPathways #HealthcareInnovation #Fibronostics
Fibronostics
Hospitals and Health Care
New Orleans, Louisiana 3,407 followers
A global diagnostics company advancing noninvasive solutions for screening, identifying,and monitoring metabolic disease
About us
Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics' LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics' HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients' risk levels and drive better patient care.
- Website
-
http://www.fibronostics.com
External link for Fibronostics
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- New Orleans, Louisiana
- Type
- Privately Held
- Founded
- 2015
- Specialties
- liver, liver health, liver disease, nafld, artificial intelligence, machine learning, non invasive , nash, and med tech
Locations
-
Primary
Get directions
615 Baronne St
Suite 100
New Orleans, Louisiana 70113, US
-
Get directions
79 Science Park Drive,Cintech IV
#06-01/08
Singapore, Singapore 118264, SG
Employees at Fibronostics
Updates
-
At EASL Congress 2026, Fibronostics will present new findings on how LIVERFASt™, used in sequential combination with vibration-controlled transient elastography (VCTE), supports the identification of ≥F3 fibrosis in patients with MASLD, including those with type 2 diabetes. The data highlights the value of integrating accessible blood-based assessment with established imaging tools to support clearer fibrosis risk stratification and clinical decision-making. Stay tuned for more from EASL 2026. #EASL2026 #ClinicalData #MASLD #T2D #Hepatology #LIVERFASt #ClinicalResearch #Fibronostics
-
-
We’re excited to share that Fibronostics will be attending American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans this June 5–8. Our team will be presenting new LIVERFASt™ data focused on identifying advanced fibrosis in patients with MASLD, including those with type 2 diabetes (T2D). Looking forward to connecting with clinicians, researchers, and partners at ADA 2026. #ADA2026 #T2D #MASLD #DiabetesCare #LiverHealth #LIVERFASt #MetabolicHealth #Fibronostics
-
-
Clinical decision-making in liver disease is rarely straightforward, especially when traditional assessment tools leave uncertainty in patient stratification. Widely used scores such as FIB-4 may leave a significant proportion of patients within indeterminate “grey zones,” potentially creating challenges in referral, follow-up, and management decisions, particularly in earlier fibrosis stages. LIVERFASt™ was designed to support clearer stratification in MASLD/MASH through a blood-based approach focused on fibrosis, steatosis, and activity assessment, with no grey zone. Studies presented by Fibronostics have demonstrated that LIVERFASt™ outperforms FIB-4 in identifying advanced fibrosis in patients with MASLD, including patients with type 2 diabetes. Clearer insights help support: • Earlier identification of at-risk patients • More confident referral decisions • Better continuity of care pathways Because clearer pathways support more consistent patient management. #ClinicalPathways #MASLD #LiverHealth #ClinicalDecisionMaking #RiskStratification #LIVERFASt #ClinicalResearch
-
-
Fibronostics will be presenting new clinical findings at EASL 2026 exploring how LIVERFASt™, in sequential combination with VCTE, supports identification of ≥F3 fibrosis in patients with MASLD, including patients with type 2 diabetes. As liver disease pathways continue to evolve, scalable and evidence-driven tools will play an increasingly important role in supporting earlier and more confident clinical decisions. We look forward to contributing to the conversation at EASL 2026. #EASL2026 #ClinicalResearch #MASLD #LiverHealth #LIVERFASt #Hepatology #Diagnostics
-
-
Many patients with significant fibrosis remain under-identified despite existing metabolic risk factors. This is especially important in patients with type 2 diabetes, where liver disease may remain clinically silent for years, and where traditional assessment tools such as FIB-4 may miss a proportion of at-risk patients, particularly at earlier fibrosis stages. Studies presented by Fibronostics have demonstrated that LIVERFASt™ outperforms FIB-4 in identifying advanced fibrosis in patients with MASLD, including those with T2D, while supporting clearer stratification with no grey zone. Clearer identification tools help support: • Earlier recognition • Better stratification • More confident clinical decisions Because identifying risk earlier changes pathways later. #MASLD #T2D #RiskStratification #LiverHealth #Diagnostics #LIVERFASt #ClinicalResearch
-
-
EASL Congress 2026 is approaching. We look forward to sharing new data on LIVERFASt™ and its role in advancing non-invasive liver diagnostics in MASLD/MASH. At EASL Congress 2026, Fibronostics will be presenting two LIVERFASt abstracts, alongside the presence of our team in Barcelona as we engage with clinicians, researchers, collaborators, and partners from around the world. Looking forward to the conversations ahead. Stay tuned. #EASL2026 #ClinicalResearch #MASLD #LiverHealth #LIVERFASt #Hepatology #Diagnostics #NonInvasiveDiagnostics #Fibronostics
-
-
LIVERFASt™ was designed to support multiple dimensions of liver health assessment through a single blood-based workflow. From screening and identification of at-risk patients… to supporting clinical pathways and longitudinal monitoring… LIVERFASt™ helps provide clinicians with structured insights across fibrosis, steatosis, and activity using common biomarkers and advanced analytics. As liver disease management continues to evolve, scalable and accessible tools will play an increasingly important role in helping support earlier detection, clearer stratification, and more confident clinical decisions. Because meaningful liver assessment should not rely on complexity alone — but on actionable insights that integrate into real-world care. #LIVERFASt #MASLD #Screening #Monitoring #ClinicalPathways #NonInvasiveDiagnostics #LiverHealth #HealthcareInnovation #Fibronostics
-
-
Liver disease often progresses silently. Many patients with advanced fibrosis may feel completely well until disease progression becomes significant — limiting opportunities for earlier intervention. This is why identifying at-risk patients earlier matters. In MASLD care, screening is not about testing everyone. It is about ensuring the right patients are not missed before disease advances. Earlier detection supports earlier action — and better patient outcomes. #Screening #EarlyDetection #MASLD #LiverHealth #PreventiveCare #LIVERFASt #Diagnostics
-
-
We’re proud to have presented new LIVERFASt™ data at Digestive Disease Week (DDW) 2026 as part of the session on Noninvasive Tools for MASLD/MASH: Real-World Performance, Pitfalls, and Clinical Integration. Presented by Dr. Mona Munteanu, the study explored correlations between LIVERFASt and MR Elastography (MRE) for fibrosis assessment, as well as intracellular fat fraction (ICFF) for steatosis assessment in patients with MASLD. The findings contribute to the growing conversation around how blood-based non-invasive diagnostics and imaging modalities can work together to support clearer clinical assessment and more informed decision-making. Thank you to Fatty Liver Allainace for highlighting the presentation and ongoing discussions around innovation in MASLD/MASH care. As the field continues to evolve, we remain committed to advancing accessible, clinically meaningful, and non-invasive approaches to liver disease assessment. #DDW2026 #MASLD #MASH #LiverHealth #Diagnostics #NonInvasiveDiagnostics #ClinicalResearch #LIVERFASt #Fibronostics
Can a blood-based test help make MASLD risk stratification more efficient? A presentation by Mona Munteanu focused on LIVERFASt, a blood-based non-invasive test designed to assess fibrosis, steatosis, and activity in patients with MASLD. The study evaluated correlations between LIVERFASt and MRI-based measures, including MRE for fibrosis and intracellular fat fraction (ICFF) for steatosis, in a single-centre cohort of 70 adults with established MASLD. The key findings: 1. Fibrosis assessment LIVERFASt Fibrosis scores increased across MRE categories: no presumed advanced fibrosis, indeterminate, and presumed advanced fibrosis. A moderate positive correlation was reported between raw scores, with Spearman r = 0.61. Under an assumption of linearity, the correlation was stronger, with Spearman r reported up to 0.86. 2. Steatosis assessment LIVERFASt Steatosis scores increased across ICFF categories, including <5%, 5% to <20%, and ≥20%. The reported correlation was moderate and consistent across analyses, with Spearman r up to 0.53. 3. Discordance matters One of the most interesting parts of the presentation was the discordance analysis between LIVERFASt and MRE. Among 21 discordant cases, integrated clinical adjudication suggested that in a meaningful proportion of cases, the discordance may have reflected limitations of the MRE surrogate standard rather than LIVERFASt alone. This included review of FIB-4, serum fibrosis biomarkers, AST/ALT ratio, and imaging signs of advanced fibrosis or cirrhosis. 4. Diagnostic performance improved after excluding presumed MRE failures Performance improved after removing presumed failures of the surrogate standard. The most notable improvement was seen in cirrhosis rule-out, where AUC increased from 0.73 to 0.84. What This Means for Clinicians FIB-4 remains useful as a first-line tool, but its limitations are well recognized, especially in older adults, people with T2D, and patients who fall into indeterminate ranges. Blood-based tools such as LIVERFASt may help refine MASLD pathways by adding quantitative, continuous risk assessment and potentially reducing reliance on imaging alone. What This Means for Patients Better non-invasive testing pathways could help identify people at risk earlier, reduce uncertainty, and support more timely follow-up before advanced liver disease is missed. This was a preliminary, retrospective, single-centre study, so broader validation is still needed. But the direction is important: MASLD care will likely require smarter combinations of simple blood tests, advanced biomarkers, imaging, and clinical judgment. #MASLD #MASH #LiverDisease #FattyLiver #Fibrosis #NITs #MRE #LIVERFASt #Hepatology #MetabolicHealth Brock Smith
-
-
-
-
-
+9
-